open access

Vol 3, No 1 (2014)
Pharmaceutical news
Published online: 2014-03-03
Get Citation

Erectile dysfunction in diabetes

Leszek Czupryniak
Diabetologia Kliniczna 2014;3(1):38-44.

open access

Vol 3, No 1 (2014)
Pharmaceutical news
Published online: 2014-03-03

Abstract

Erectile dysfunction (ED) is one of the most prevalent chronic complications of diabetes, the one which is also severely impairing patients’ quality of life. However, it is also often undiagnosed and remains untreated. Erectile dysfunction in diabetes may result from vascular, neurological (autonomic neuropathy), hormonal (hypogonadism) and local lesions. Old age, sedentary lifestyle, obesity, dyslipidemia, hypertension, certain medications, smoking, alcohol abuse and depression are all important risk factors for ED development. International Index of Erectile Function-5 (IIEF-5) questionnaire is a useful self-administered tool for ED diagnosis. Management of ED includes improving blood glucose, blood pressure and lipids control as well as weight reduction, smoking cessation and decrease in alcohol intake. Psychological counselling should be offered to all patients. Phosphodiesterase inhibitors type 5 are drugs of choice, with sildenafil having been available for over 15 years. In majority (up to 70%) of patients these agents are effective in respect to improving erection quality. Other therapeutic options are prostaglandin E analog (alprostadil) injections or testosterone gel. In those patient in whom pharmacotherapy fails, medical devices or prosthesis can be used.

Abstract

Erectile dysfunction (ED) is one of the most prevalent chronic complications of diabetes, the one which is also severely impairing patients’ quality of life. However, it is also often undiagnosed and remains untreated. Erectile dysfunction in diabetes may result from vascular, neurological (autonomic neuropathy), hormonal (hypogonadism) and local lesions. Old age, sedentary lifestyle, obesity, dyslipidemia, hypertension, certain medications, smoking, alcohol abuse and depression are all important risk factors for ED development. International Index of Erectile Function-5 (IIEF-5) questionnaire is a useful self-administered tool for ED diagnosis. Management of ED includes improving blood glucose, blood pressure and lipids control as well as weight reduction, smoking cessation and decrease in alcohol intake. Psychological counselling should be offered to all patients. Phosphodiesterase inhibitors type 5 are drugs of choice, with sildenafil having been available for over 15 years. In majority (up to 70%) of patients these agents are effective in respect to improving erection quality. Other therapeutic options are prostaglandin E analog (alprostadil) injections or testosterone gel. In those patient in whom pharmacotherapy fails, medical devices or prosthesis can be used.

Get Citation

Keywords

diabetes, autonomic neuropathy, erectile dysfunction, sildenafil

About this article
Title

Erectile dysfunction in diabetes

Journal

Clinical Diabetology

Issue

Vol 3, No 1 (2014)

Pages

38-44

Published online

2014-03-03

Bibliographic record

Diabetologia Kliniczna 2014;3(1):38-44.

Keywords

diabetes
autonomic neuropathy
erectile dysfunction
sildenafil

Authors

Leszek Czupryniak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl